Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good day, and welcome to the ARS Pharmaceuticals Third Quarter ...

ARS Pharmaceuticals shares jumped Monday after the company inked a deal to commercialize its allergic reaction nasal spray internationally.

Commercial launch of neffy®(epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by ...

ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak ...

ARS Pharmaceuticals (SPRY) announced a licensing agreement with ALK-Abello A/S (AKBLF), that provides ALK exclusive rights to commercialize ...

Although ARS Pharmaceuticals’ approval for its epinephrine nasal spray came later than expected, the company ultimately received a thumbs up from the FDA in August and is now moving fast to expand ...

ALK licenses rights to adrenaline nasal spray, neffy from ARS Pharma for emergency treatment of allergic reactions: Hørsholm, Denmark Tuesday, November 12, 2024, 12:00 Hrs [IST] ...

ALK will also pay up to $320m in milestone payments to ARS in the deal, which sees the latter keep rights in the US, ...

Musk—the CEO of Tesla and SpaceX, and owner of X (formerly Twitter)—was quoted in Trump's announcement as saying that DOGE ...

ALK’s CEO, Peter Halling, said: “We are excited about the deal with ARS Pharma. It is an important step in ALK’s strategic efforts to establish leading positions in anaphylaxis, food allergy ...

Exclusive rights to new indications ARS Pharma is also developing its intranasal adrenaline (epinephrine) technology for the treatment of acute flares in patients with chronic urticaria ...

ALK’s CEO, Peter Halling, said: “We are excited about the deal with ARS Pharma. It is an important step in ALK’s strategic efforts to establish leading positions in anaphylaxis, food allergy, and new ...